GlassScriptPhysician profile
Laurie Komuda
NPI 1942759568
$2,691.10
in general payments reported to CMS, 2019-2025
25 companies · $258 in 2025
The $258 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $359 · 2022: $477 · 2023: $1,122 · 2024: $475 · 2025: $258.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,844 · Education: $10.53.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,844.40 |
| Education | $10.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $380.98 | 2022-2025 | Epclusa |
| Abbvie INC. | $334.27 | 2022-2024 | |
| Janssen Pharmaceuticals, INC | $250.99 | 2021-2025 | Invega, Spravato, Invega Sustenna |
| Otsuka America Pharmaceutical, INC. | $206.69 | 2022-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Lundbeck LLC | $200.90 | 2022-2024 | Rexulti |
| Indivior INC. | $183.42 | 2022-2024 | Perseris, Sublocade |
| Teva Pharmaceuticals USA, INC. | $178.84 | 2022-2025 | Uzedy, Austedo Xr, Austedo |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $167.34 | 2022-2024 | Caplyta |
| Alkermes, INC. | $115.26 | 2023-2025 | Aristada, Lybalvi, Vivitrol |
| Neurocrine Biosciences, INC. | $73.18 | 2022-2024 | Ingrezza |
| Orexo US, INC. | $71.68 | 2022-2023 | Zubsolv |
| Vanda Pharmaceuticals INC. | $70.57 | 2025 | Fanapt, Hetlioz |
| Pfizer INC. | $67.64 | 2021 | |
| Medtronic, INC. | $67.40 | 2021 | |
| Corium, LLC | $65.38 | 2022-2023 | Azstarys |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.17 | 2021 | |
| Amgen INC. | $32.86 | 2021 | |
| Braeburn INC. | $31.33 | 2024 | Brixadi |
| E.R. Squibb & Sons, L.L.C. | $30.02 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $26.10 | 2021 | |
| Axsome Therapeutics, INC. | $24.22 | 2023 | Auvelity |
| Avanir Pharmaceuticals, INC. | $21.97 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $16.54 | 2021 | |
| Novartis Pharmaceuticals Corporation | $14.77 | 2021 | |
| Merck Sharp & Dohme LLC | $14.58 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laurie Komuda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.